Methylglyoxal Modified Proteins Antikörper

Produktnummer ABIN2192148

Der Maus Monoklonal anti-Methylglyoxal Modified Proteins Antikörper (Klon MGO-1) (ABIN2192148) detektiert spezifisch Methylglyoxal Modified Proteins in IHC (p), WB und IA. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Methylglyoxal Modified Proteins Antikörper (ABIN2192148)

Target: Methylglyoxal Modified Proteins

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB), Immunoassay (IA)

Klon: MGO-1

Produktdetails

Kreuzreaktivität (Details): Cross reactivity: Multispecies : Yes

Sterilität: 0.2 μm filtered

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Antigendetails

Target: Methylglyoxal Modified Proteins

Hintergrund: The monoclonal antibody MGO-1recognizes human MGO modified proteins. Methylglyoxal (MGO) is an endogenous product of glucose metabolism. Increased production and accumulation of methylglyoxal (MGO), as well as increased modification of proteins by glycoxidation, are hallmarks of aging and diabetes. MGO was shown to modify proteins and to contribute to the accumulation of damaged proteins that can be toxic to cells. A number of studies have shown that MGO levels are significantly elevated in patients with Type 2 Diabetes and correlates well with fasting plasma glucose and hemoglobin A1c (HbA1c) levels. Moreover, increased formation of the MGO is implicated in renal dysfunction and is known to be involved in the development of DN (diabetic nephropathy). Immunogen MGO-modified KLH